

## The UK Chemotherapy Board Meeting

<b>Meeting Date and Time</b>	Thursday 7th June 2022 1-4pm	<b>Meeting Location</b>	Zoom Meeting
<b>Meeting Chair</b>	Lisa Barrott and Catherine Oakley	<b>Minutes</b>	Meegan Adkins

<b>1.</b>	<p><b>Welcome, apologies and declaration of conflicts of interest</b></p> <p>Attendance:</p> <table border="1"> <tr><td>Lisa Barrott (Chair)</td><td>UK Oncology Nursing Society (UKONS)</td></tr> <tr><td>Catherine Oakley (Chair)</td><td>UK Oncology Nursing Society (UKONS)</td></tr> <tr><td>Alia Nizam</td><td>National Regimen Specific Consent Forms</td></tr> <tr><td>Catherine Bale</td><td>Wales</td></tr> <tr><td>Danya Abdulwahid</td><td>The Royal College of Radiologists (RCR)</td></tr> <tr><td>David Cameron</td><td>Scotland</td></tr> <tr><td>David Hobin</td><td>Oncology Representative (CCLG)</td></tr> <tr><td>Denise Bonney</td><td>Haematology Representative (CCLG)</td></tr> <tr><td>Emma Kipps</td><td>SACT Lead</td></tr> <tr><td>Janine Mansi</td><td>National Regimen Specific Consent Forms</td></tr> <tr><td>John Ashcroft</td><td>Royal College of Pathologists (RCPath)</td></tr> <tr><td>Martine Bomb</td><td>NHSD SACT Dataset Team</td></tr> <tr><td>Netty Cracknell</td><td>British Oncology Pharmacy Association (BOPA)</td></tr> <tr><td>Paula Scullin</td><td>Northern Ireland</td></tr> <tr><td>Pinkie Chambers</td><td>British Oncology Pharmacy Association (BOPA)</td></tr> <tr><td>Roshan Agarwal</td><td>The Royal College of Physicians / The Association of Cancer Physicians (RCP / ACP)</td></tr> <tr><td>Ruth Board</td><td>The Royal College of Physicians / The Association of Cancer Physicians (RCP / ACP)</td></tr> <tr><td>Tom Roques</td><td>The Royal College of Radiologists (RCR)</td></tr> </table> <p>Apologies/Not in attendance:</p> <table border="1"> <tr><td>Anne Rigg</td><td>Chemotherapy Clinical Reference Group</td></tr> <tr><td>Edna Young</td><td>Lay representative</td></tr> <tr><td>Gordon Cook</td><td>Royal College of Pathologists (RCPath)</td></tr> <tr><td>Hannah Tharmalingam</td><td>The Royal College of Radiologists (RCR)</td></tr> <tr><td>John Ashcroft</td><td>Royal College of Pathologists (RCPath)</td></tr> <tr><td>Nicky Thorp</td><td>The Royal College of Radiologists (RCR)</td></tr> <tr><td>Pippa Corrie</td><td>Cancer Clinical Specialty Lead, National Institute for Health Research</td></tr> </table> <p>The Chair welcomed all to the meeting. There were no declarations of conflicts of interest.</p> <p>Apologies for absences were as listed above. In addition to this, it was noted that Emma Kipps would join from 1.30pm onwards and Catherine Oakley may need to leave early.</p>	Lisa Barrott (Chair)	UK Oncology Nursing Society (UKONS)	Catherine Oakley (Chair)	UK Oncology Nursing Society (UKONS)	Alia Nizam	National Regimen Specific Consent Forms	Catherine Bale	Wales	Danya Abdulwahid	The Royal College of Radiologists (RCR)	David Cameron	Scotland	David Hobin	Oncology Representative (CCLG)	Denise Bonney	Haematology Representative (CCLG)	Emma Kipps	SACT Lead	Janine Mansi	National Regimen Specific Consent Forms	John Ashcroft	Royal College of Pathologists (RCPath)	Martine Bomb	NHSD SACT Dataset Team	Netty Cracknell	British Oncology Pharmacy Association (BOPA)	Paula Scullin	Northern Ireland	Pinkie Chambers	British Oncology Pharmacy Association (BOPA)	Roshan Agarwal	The Royal College of Physicians / The Association of Cancer Physicians (RCP / ACP)	Ruth Board	The Royal College of Physicians / The Association of Cancer Physicians (RCP / ACP)	Tom Roques	The Royal College of Radiologists (RCR)	Anne Rigg	Chemotherapy Clinical Reference Group	Edna Young	Lay representative	Gordon Cook	Royal College of Pathologists (RCPath)	Hannah Tharmalingam	The Royal College of Radiologists (RCR)	John Ashcroft	Royal College of Pathologists (RCPath)	Nicky Thorp	The Royal College of Radiologists (RCR)	Pippa Corrie	Cancer Clinical Specialty Lead, National Institute for Health Research	<b>Chair</b>
Lisa Barrott (Chair)	UK Oncology Nursing Society (UKONS)																																																			
Catherine Oakley (Chair)	UK Oncology Nursing Society (UKONS)																																																			
Alia Nizam	National Regimen Specific Consent Forms																																																			
Catherine Bale	Wales																																																			
Danya Abdulwahid	The Royal College of Radiologists (RCR)																																																			
David Cameron	Scotland																																																			
David Hobin	Oncology Representative (CCLG)																																																			
Denise Bonney	Haematology Representative (CCLG)																																																			
Emma Kipps	SACT Lead																																																			
Janine Mansi	National Regimen Specific Consent Forms																																																			
John Ashcroft	Royal College of Pathologists (RCPath)																																																			
Martine Bomb	NHSD SACT Dataset Team																																																			
Netty Cracknell	British Oncology Pharmacy Association (BOPA)																																																			
Paula Scullin	Northern Ireland																																																			
Pinkie Chambers	British Oncology Pharmacy Association (BOPA)																																																			
Roshan Agarwal	The Royal College of Physicians / The Association of Cancer Physicians (RCP / ACP)																																																			
Ruth Board	The Royal College of Physicians / The Association of Cancer Physicians (RCP / ACP)																																																			
Tom Roques	The Royal College of Radiologists (RCR)																																																			
Anne Rigg	Chemotherapy Clinical Reference Group																																																			
Edna Young	Lay representative																																																			
Gordon Cook	Royal College of Pathologists (RCPath)																																																			
Hannah Tharmalingam	The Royal College of Radiologists (RCR)																																																			
John Ashcroft	Royal College of Pathologists (RCPath)																																																			
Nicky Thorp	The Royal College of Radiologists (RCR)																																																			
Pippa Corrie	Cancer Clinical Specialty Lead, National Institute for Health Research																																																			



	There was an agreement to repeat this item at the next Board meeting in October 2022 and the Chair requested that Michael Tilby stayed for the next item on Extravasations.	
5.	<p><b>Extravasation - update</b></p> <p>The Chair introduced Andrew Barton, Chair of the National Infusion Vascular and Access Society (NIVAS).</p> <p>NIVAS was approached by NHS Resolution to help build a national strategy about best awareness prevention and treatment based on a review of claims. Andrew has joined a group chaired by Elaine Tomlins from the Royal Marsden, which includes representation from all areas interested in extravasation. National guidelines and patient information are under development for Chemotherapy and non-chemotherapy drugs. There were no pre-existing national non-chemo extravasation guidelines.</p> <p>An awareness campaign was being developed as part of a patient advocacy group. <b>Action: Andrew Barton to circulate the 'Did you know?' leaflet about extravasations to members of the Board to disseminate.</b></p> <p>The goal was to standardise the classification of extravasation, treatment pathways, and reporting methods. The Chair noted that an Oncology metric on extravasations would be extremely helpful.</p>	<p><b>Andrew Barton</b></p> <p><b>Action</b></p>
6.	<p><b>Chemotherapy Board Work Streams</b></p>	<b>Chair</b>
6a.	<p><b>Chemotherapy consent forms and related documents – update</b></p> <p>An overview of recent meetings that had taken place and progress that had been made since the last meeting of the Board was provided. Two forms (Thyroid SACT and Kadcyia) had been revalidated and a new consent form (atezolizumab - paklitaxel albumin bound) had been approved. The generic forms for several Tumour Groups were in the final stages of revalidation and the expectation was that they would be uploaded within a fortnight of this meeting.</p> <p>The Patient Questionnaire has been revised and would start being used imminently. A final list of SACT Leads was being compiled to enable the Clinician Survey Questionnaires to be distributed. This was to better understand which Trusts were using the forms, as the current analytics couldn't provide this information.</p> <p>Discussions were underway to try and improve the functionality of existing E-Consent documents to make them editable, specifically the use of tick boxes and incorporating electronic signatures.</p> <p>The RCR were in the process of developing Chemo-Rad forms and requested input to an Expert Panel Meeting on their Bladder document, which had been reviewed and feedback provided.</p> <p>The cause and location of a spike in downloads during October were still unknown. The Generic forms continued to be the third most downloaded forms, after Breast and Colorectal. A breakdown of the Tumour-Specific downloads by Country was now available and further analysis would be provided at a future meeting.</p> <p>The Board queried the current funding arrangements, they were done on a rolling basis and would be reviewed next September 2023. Funding arrangements were previously agreed for up to two years but it hadn't been possible to make a permanent agreement. The Chair noted that succession planning would need consideration. <b>Action: Netty Cracknell and Janine Mansi to explore potential funding options for National SACT Consent Forms and Protocols.</b></p>	<p><b>Alia Nizam</b></p> <p><b>Action</b></p>
6b.	<p><b>Intrathecal Chemotherapy Standards – update</b></p> <p>This was significantly delayed for several reasons including operational pressures. A steering group had been established and the group now had access to archived measures, which would be reviewed and updated taking into consideration that Nurse Practitioners were to take on the administration of intrathecal treatments.</p>	<b>Lisa Barrott</b>
6c.	<p><b>National SACT protocols – update</b></p> <p>A meeting was held to discuss how to progress the programme, including funding. A formal proposal was in development and would be shared with the Board. Further information was requested on the scope of the programme, it was likely that it would start with a small number of new protocols, and whether to later review established protocols was yet to be decided. The Chair acknowledged the size and importance of the project, especially given the learnings from Consent Forms.</p>	<b>Netty Cracknell</b>
6d.	<p><b>Standards for Reducing Risks Associated with Electronic Prescribing – update</b></p> <p>The standards have now been published. There was an agreement to close the work stream until a revision was required.</p>	<b>Netty Cracknell</b>
6e.	<p><b>Steroid prophylaxis for immunotherapy – update</b></p> <p>Discussed as part of Item 12.</p>	<b>Pinkie Chambers</b>
6f.	<p><b>National consensus on validity periods of blood tests and threshold values – update</b></p> <p>There were inconsistencies across the threshold values in the UK and levels that were set too high had been seen to cause unnecessary delays in treatment. The threshold values would differ between regimens. A pilot was ready, and participants were being recruited.</p>	<b>Pinkie Chambers</b>



12.	<p><b>Guidelines from management of Hypersensitivity to SACT – position statement</b></p> <p>UKONS has seen an increasing number of member questions about how SACT Units were managing hypersensitivity reactions. This had been triggered by recent guidance on not utilising hydrocortisone in anaphylaxis management. The guidance specified that it was for airway and circulatory problems, but the Board agreed that it was ambiguous advice and caused confusion.</p> <p>Danya Abdulwahid showed an interest in scoping the project. <b>Action: Danya Abdulwahid to contact the Resuscitation Council UK to see whether there was an appetite to create a joint position statement specifically for the management of hypersensitive reactions of patients receiving SACT.</b></p> <p>The Chair acknowledged some members’ concerns about the size of some of the projects being taken on. The Board agreed that the projects were very much a priority and that it was the correct forum for such a position statement.</p>	<p>Lisa Barrott</p> <p><b>Action</b></p>
13.	<p><b>TMPT and NUDT15 pharmacogenomic dosing guidelines – to be reviewed</b></p> <p>NHS England had approved routine genomic testing for SACT and logistics on how to deliver this nationally were being worked through. Dosing guidelines were being developed and the Board had been approached to review or approve these.</p> <p>The Board discussed whether it was appropriate for them to provide approval or guidance. Members agreed that promoting and disseminating documents was in their remit. It wasn’t clear from the request what was being asked of the Board. <b>Action: Netty Cracknell to seek further clarity on what was required by the Board for new pharmacogenomic dosing guidelines.</b></p>	<p>Netty Cracknell</p> <p><b>Action</b></p>
14.	<p><b>Any Other Business</b></p> <p><b>Name Change</b></p> <p>A change of the name for the UK Chemotherapy Board to the UK SACT Board was proposed. This was initially suggested a few years ago but the decision was made that, although ‘Chemotherapy’ didn’t adequately encompass all the areas the Board covered, SACT wasn’t a well-understood enough term and would create confusion.</p> <p>The Chair confirmed that the Terms of Reference for the Board specified that it also included immunotherapy, but that SACT was more widely used now, including internationally, and the Board agreed it was the preferred term. <b>Action: Lisa Barrott and Catherine Oakley to seek approval to change the name to the UK SACT Board from RCPaTH and communicate the outcome to the Board.</b></p> <p>The issue was raised again recently because a national immunotherapy board was being scoped. There was a further discussion about how a UK Immunotherapy Board would work. <b>Action: Ruth Board to contact the Chair of the proposed UK Immunotherapy Board to discuss the scope of the group, including how it will be aligned with the UK Chemotherapy Board, and provide feedback to the group.</b></p> <p>The Chair noted that it would be a good opportunity to review the website and also look at developing a logo.</p>	<p>Chair</p> <p><b>Action</b></p> <p><b>Action</b></p>
15.	<p><b>Dates of Next Meeting</b></p> <ul style="list-style-type: none"> <li>Thursday 13<sup>th</sup> October 2022: 2pm to 4pm – Virtual</li> </ul>	<p>Chair</p>